DexCom (NASDAQ:DXCM) Reaches New 1-Year High at $174.51

DexCom, Inc. (NASDAQ:DXCM)’s share price hit a new 52-week high on Thursday . The company traded as high as $174.51 and last traded at $173.67, with a volume of 774 shares traded. The stock had previously closed at $173.19.

Several equities analysts recently commented on DXCM shares. UBS Group increased their price objective on shares of DexCom from $140.00 to $160.00 and gave the company a “neutral” rating in a research note on Thursday, August 1st. BMO Capital Markets increased their price objective on shares of DexCom from $167.00 to $172.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. TheStreet upgraded shares of DexCom from a “d+” rating to a “c” rating in a research report on Friday, June 28th. ValuEngine cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Bank of America increased their price objective on shares of DexCom from $162.00 to $185.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Six research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $166.75.

The company has a debt-to-equity ratio of 1.56, a current ratio of 6.05 and a quick ratio of 5.64. The firm has a market capitalization of $15.85 billion, a price-to-earnings ratio of 580.78 and a beta of 0.80. The business’s fifty day simple moving average is $152.58 and its 200 day simple moving average is $137.15.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Wednesday, July 31st. The medical device company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.07. The business had revenue of $336.40 million during the quarter, compared to analysts’ expectations of $304.40 million. DexCom had a negative net margin of 13.96% and a positive return on equity of 10.41%. The business’s quarterly revenue was up 38.7% on a year-over-year basis. During the same period last year, the company posted ($0.10) earnings per share. Equities research analysts expect that DexCom, Inc. will post 0.97 earnings per share for the current fiscal year.

In other news, EVP Steven Robert Pacelli sold 3,116 shares of DexCom stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $149.65, for a total transaction of $466,309.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Kevin R. Sayer sold 10,000 shares of DexCom stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $156.12, for a total transaction of $1,561,200.00. The disclosure for this sale can be found here. Insiders sold 62,068 shares of company stock valued at $8,485,669 over the last 90 days. Corporate insiders own 1.80% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of DXCM. Geode Capital Management LLC grew its holdings in DexCom by 17.2% in the fourth quarter. Geode Capital Management LLC now owns 1,042,131 shares of the medical device company’s stock worth $124,776,000 after purchasing an additional 152,781 shares during the period. Dimensional Fund Advisors LP grew its holdings in DexCom by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 164,763 shares of the medical device company’s stock worth $19,738,000 after purchasing an additional 3,468 shares during the period. Pennsylvania Trust Co acquired a new stake in DexCom in the first quarter worth $4,864,000. Strs Ohio grew its holdings in DexCom by 59.0% in the first quarter. Strs Ohio now owns 2,304 shares of the medical device company’s stock worth $274,000 after purchasing an additional 855 shares during the period. Finally, CWM LLC grew its holdings in shares of DexCom by 22.1% during the first quarter. CWM LLC now owns 39,875 shares of the medical device company’s stock valued at $4,749,000 after buying an additional 7,205 shares during the last quarter. Hedge funds and other institutional investors own 94.19% of the company’s stock.

About DexCom (NASDAQ:DXCM)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Further Reading: Technical Analysis of Stocks and What It Means

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.